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In spite of increasing resistance to current anti-
bacterial agents, large pharmaceutical companies
have been exhibiting greater reluctance to remain
in the business of drug discovery for new agents
to treat these resistant pathogens. After a ﬂurry of
research and development activity in the 1990s to
produce drugs to treat multidrug-resistant Gram-
positive bacteria, a number of large companies
have either terminated or greatly curtailed their
antibacterial research efforts. This has resulted in
an outcry from infectious disease opinion leaders
and regulatory agencies. Some of the companies
that reduced or eliminated their own research in
anti-infectives due to commercial considerations
then relied on biotech companies to become their
surrogate research organisations. At the same
time, other companies have continued their
efforts to identify new antibacterial agents to
meet emerging medical needs caused by unre-
lentingly evolving resistance, especially in Gram-
negative pathogens. It is imperative that these
companies be encouraged to continue their efforts
to avoid an impending crisis in the treatment of
infectious diseases. In addition, companies previ-
ously active in the ﬁeld should be encouraged to
return.
At the 2003 Interscience Conference on Anti-
microbial Agents and Chemotherapy (ICAAC)1 a
symposium entitled Why is Big Pharma Getting
Out of Anti-Infective Drug Discovery? featured a set
of presentations addressing these issues. In this
supplement different aspects of antibiotic re-
search and the need for new agents are discussed,
based on many of the topics presented at the
ICAAC symposium. An academic viewpoint
regarding the status of antibiotic resistance is
provided. Representatives from large companies,
as well as biotechs, have presented some of the
common thinking surrounding decisions to stay
in, or to retreat from, antibacterial research. In
addition, the state of play is presented through
the viewpoint of a representative from the FDA.
Throughout all these articles is the recurring
theme of resistance, and the continuing selection
of multidrug-resistant pathogens.
Although the articles in this supplement cover
various aspects of research, development and
regulatory issues, there is no easy response to the
basic commercial issues of treatment of acute
disease rather than chronic illness. The fact that
antibacterial agents are frequently used to treat
life-threatening infections is often forgotten, when
the return on investment may not be as attractive
as for agents to treat lifestyle modiﬁcations, or
mild chronic disease. However, it is imperative
that those who understand the long-term impli-
cations continue to provide possible solutions to
the pharmaceutical companies, either to continue
their efforts if they are still in the area, or to entice
them back into the ﬁeld if they have recently
exited. The recent initiatives proposed by the
Infectious Diseases Society of America provide a
positive set of proposals for the encouragement of
antibacterial research and development at the
basic level, and serve to set an example for the
kind of forward thinking that must be underta-
ken. It is especially critical that the infectious
disease community work together to educate
those outside the anti-infective ﬁeld as to the
importance of continuing the basic research and
development of new agents to treat multidrug-
resistant infections. Perhaps this supplement will
provide additional insight into the questions that
have been raised over the past year, resulting in a
reconsideration of decisions made by companies
that still have research teams intact. The need for
new agents will not disappear. We must hope that
there will be new drugs emerging from the
pipeline to treat them.
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